Title

A Phase I Study of Quadrivalent HPV Recombinant Vaccine
A Randomized, Double-Blind and Placebo-Controlled Phase I Study to Evaluate the Safety and Primary Immunogenicity of the Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 9-45 Years
  • Phase

    Phase 1
  • Study Type

    Interventional
  • Status

    Completed No Results Posted
  • Study Participants

    90
To evaluate the safety and primary immunogenicity of the quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (hansenula polymorpha) in Chinese female subjects aged 9-45 years.
Study Started
Dec 31
2016
Primary Completion
Oct 31
2017
Study Completion
Aug 31
2018
Last Update
Sep 14
2018

Biological HPV vaccine

Biological Placebo

HPV vaccine Experimental

Subjects received 3 doses of HPV vaccine according to a 0, 2, 6-month schedule.

Placebo Placebo Comparator

Subjects received 3 doses of Placebo according to a 0, 2, 6-month schedule.

Criteria

Inclusion Criteria:

Healthy females between, and including, 9 and 45 years of age at the time of enrolment
Be able to provide legal identification for the sake of recruitment
Be able to understand and sign informed consent form prior to enrollment and for subjects aged 9-17 years, they and their legal guardian(s) are supposed to understand and sign informed consent form together
Subjects who the investigator believes that they can and will comply with the protocol requirements
Subject must be not pregnant at the enrollment and agree to use adequate contraceptive precautions within 7 months or don't have pregnancy plan

Exclusion Criteria:

Fever or axillary temperature> 37.0℃ before vaccination
Previous vaccination against HPV, or planned administration/administration of a vaccine not foreseen by the study protocol within 30 days preceding first dose of vaccine; Planned to take part in other clinical research within 7 months after participating this study
Abnormal laboratory tests parameters
Administration of any whole blood, plasma or immunoglobulins products within 3 months preceding first vaccination
Interval between administration of the study vaccination and any attenuated live vaccine less than 14 days, and other vaccines less than 10 days
History of serious allergic disease requiring medical intervention (such as oral and throat swelling, difficulty breathing, hypotension or shock)
History of to adverse event to vaccine, or allergic to some food or drug
History of epilepsy, seizures or convulsions, or family history of mental illness
Subjects are immunocompromised or have been diagnosed as suffering from congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis inflammation (JRA), inflammatory bowel disease or other autoimmune diseases, administration of immunosuppressants with six months prior to the first vaccine dose.
Asplenia, functional asplenia, or any circumstances result of asplenia or splenectomy
Subject to severe hepatorenal disease, cardiovascular disease, hypertension, diabetes, malignant tumor, all kinds of infectious diseases and acute illness, or during chronic disease acute attack period
Medical diagnosis of coagulation abnormalities (eg, clotting factor deficiency, coagulation disorders, platelet anomaly) or obvious bruising or coagulation disorder
During menstrual period or acute disease period of onset
Breastfeeding, pregnancy (including pregnancy test positive), or planned to be pregnant within 7 months
Abnormal cervical cancer screening or subject to CIN or acuteness wet wart that relevant to HPV infection in the past two years
Planned to moveout of local before the end of the study or leave the local for a long time during the study period
Other unsuitable factors for the study judged by investigators
No Results Posted